EPTIS
BAM Logo

SARS-CoV-2 Proficiency Testing Scheme

EPTIS Ringversuch Nr. 769005 | Letze Änderung 2022-05-04 | URL: https://www.eptis.bam.de/pts769005 https://www.eptis.bam.de/pts769005

Name des Anbieters
Name des Anbieters LGC AXIO Proficiency Testing LGC AXIO Proficiency Testing
Ansässig in United Kingdom
Sprache(n)
Anmerkungen The primary aim of the Clinical Laboratory proficiency testing scheme (CLS) is to enable laboratories performing analysis of clinical samples to monitor their performance and compare it with that of their peers. The CLS scheme also aims to provide information to participants on technical issues and methodologies relating to Clinical Laboratory Science. The CLS scheme year operates from January to December. Further information about CLS, including test material availability, round despatch dates and reporting deadlines, are available on the current CLS application form. The operation of the scheme is supported by an Advisory Group consisting of experts in the field of Clinical Laboratory Science and proficiency testing. The scheme reports on the performance of U.K. participants to the National Quality Assurance Advisory Panels for Chemical Pathology and for Medical Microbiology.
Klassifizierung
Produktgruppen Human test material
Prüfgebiete Biology
Medical analysis
Microbiology
Technische Einzelheiten
Prüfobjekt Prüfeigenschaft Prüfmethode
SARS-CoV-2 (Serological)- 3 x 0.75 ml samples for detection for the SARS-CoV-2 antibodies -NEW 2020 SARS-CoV-2 IgA, IgG, IgM, Total antibodies The samples are suitable for antibody detection methods
The samples are derived from naturally occurring material collected via apheresis from patients that have recovered from COVID-19.
Qualitative (presence/absence)
SARS-CoV-2 (Molecular)- 2 x 1.5ml samples for SARS-CoV-2 virus -NEW 2020 SARS-CoV-2 virus The samples are suitable for methods that target the CDC/WHO consensus genomic RNA sequences
The samples contain the whole genome.
Qualitative (presence/absence)
SARS-CoV-2 antigen - 3 x swab based samples (A, B, and C). Non-infectious simulated patient nasopharyngeal samples containing the SARS-CoV-2 nucleocapsid protein. SARS-CoV-2 virus Qualitative (presence/absence)
SARS-CoV-2 (Molecular)- 2 x swab based samples. Non-infectious simulated nasopharyngeal samples containing the SARS-CoV-2 genome. The samples contain the whole genome SARS-CoV-2 virus - The samples contain the whole genome Qualitative (presence/absence)
SARS-CoV-2 Quality Control Pack SARS-CoV-2 virus - The samples contain the whole genome Qualitative (presence/absence)
Ringversuchsziele
Zielgruppe des Ringversuchs Clinical laboratories, other
Relevante Rechtsvorschriften oder Normen
Weitere Ziele validation of testing methods
Teilnehmerzahl
Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt)

Akkreditiert durch A2LA, UKAS, ILAV-MRA auf der Grundlage von ISO/IEC 17043:2010 nicht für alle Parameter

Die Durchführung des Ringversuchs ist in Auftrag gegeben durch
Kosten
Teilnahmegebühr Fees vary according to selection from available groups.
Regelmässig durchgeführt Ja (12 rounds per year)
Der Ringversuch wird durchgeführt seit 2018
Kontaktdaten des Anbieters
Anbieter Kontaktperson
LGC AXIO Proficiency Testing
1 Chamberhall Business Park, Chamberhall Green
BL9 0AP Bury, Greater Manchester
United Kingdom

Telefon: +44 (0)161 762 2500
Fax: +44 (0)161 762 2501
Web: https://www.lgcstandards.com/GB/en/Proficiency-Testing/cat/244597 https://www.lgcstandards.com/GB/en/Proficiency-Testing/cat/244597
Mrs Nicola Armstrong
Telefon: +44 (0)161 762 2500
Fax:
E-Mail: axiopt@lgcgroup.com axiopt@lgcgroup.com
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom, Mr Savvas Xystouris. Mr Savvas Xystouris.
Haben Sie Fragen? Senden Sie uns eine E-Mail: eptis@bam.de.
Anwendungsversion: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5